Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients

Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00741520

Acronym

OSA-NORMO

Enrollment

Registered

2008-08-26

Start date

2008-08-31

Completion date

2010-07-31

Last updated

2010-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

Obstructive Sleep Apnea, Blood Pressure, PreHypertension, Masked Hypertension

Brief summary

Recent evidences suggest that obstructive sleep apnea (OSA) can contribute to cardiovascular disease even in the absence of hypertension. However, there are few data regarding the impact of OSA on the preHypertension and Masked Hypertension in apparently normotensive patients with OSA as well as the impact of treatment with continuous positive airway pressure.

Interventions

DEVICECPAP

Control - no treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

MALE

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Severe OSA patients

Exclusion criteria

* Smoking * Sustained Hypertension * Heart failure * Diabetes * Renal diseases * Under use of any medication * Under treatment for OSA

Design outcomes

Primary

Measure	Time frame	Description
Office Blood Pressure	—	Evaluation of PreHypertension

Secondary

Measure	Time frame	Description
24 Hour Ambulatory Blood Pressure Monitoring	—	Evaluation of Masked Hypertension

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026